(RTTNews) - The following biotech stocks reached a 52-week high on September 8, 2026, driven by a series of clinical developments and important regulatory milestones. Pharvaris N.V. (PHVS) Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for the treatment of bradykinin-mediated hereditary angioedema (HAE). The company's stock rose over 7% to a 52-week high of $43.25 on Tuesday. In the second quarter, Pharvaris' net loss increased to EUR 47.8 million, compared to EUR 45.5 million in the previous year. On Tuesday, the company announced positive topline results from the Phase 3 CHAPTER-3 trial for its lead drug, Deucrictibant, in treating hereditary angioedema (HAE). The drug was found to decrease HAE attacks by 87% in treated patients. The U.S. Food and Drug Administration (FDA) accepted the NDA for deucrictibant in July 2026 and may provide a response by April 23, 2027. Roivant Sciences Ltd. (ROIV) Roivant Sciences is a commercial-stage biopharmaceutical company developing medicines that target various autoimmune diseases. On Tuesday, the company saw shares climb over 6% to a new 52-week high of $42.50 in the intraday trade. Roivant reported positive topline results from the Phase 2 PHocus trial for Mosicliguat in treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). Data indicates that the drug met the study's primary endpoint, and will now be evaluated in the global Phase 3 PHrontier trial. Last month, the company received FDA approval for LISRAYA in the treatment of dermatomyositis. BlossomHill Therapeutics Inc. (BLSM) Blossom Hill Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for the treatment of rare cancers. Shares climbed over 4% to a 52-week high of $23.37 on Tuesday. The company began trading on the Nasdaq Global Select Market on August 7, 2026. Earning about $150 million in an initial public offering (IPO). Earlier this month, BlossomHill received a Fast Track designation from the U.S. Food and Drug Administration (FDA) for BH-30643 in advanced or metastatic non-small cell lung cancer (NSCLC), as a Phase 1/2 study for the drug completes enrolment. BH-30643 is the company's lead drug candidate, and showed effective inhibition of cancer cells with EGFR mutations in preclinical studies. AtriCure Inc. (ATRC) AtriCure provides various technologies to treat Atrial fibrillation or Afib, which is an irregular heart rhythm originating in the upper heart chambers known as atria. Shares reached a 52-week high of $55.72 on Tuesday. Among the company's products is the Isolator Synergy surgical ablation system, used to repair faulty atrial walls that cause Afib. The system was the first medical device for treating persistent Afib that received FDA approval. Other treatments include AtriClip, that acts as a left atrial appendage (LAA) exclusion system, the minimally invasive Hybrid AF therapy, and the cryoICE cryoSPHERE and cryoXT probes for temporary ablation to block peripheral nerve signaling. For the second quarter of this year, the company reported a revenue of $153.6 million, reflecting a 12.8% growth. Revenue for the full year of 2026 are estimated between $602 million and $610 million, considerably higher than the $534 million recorded last year. Faeth Therapeutics Inc. (FTH) Faeth Therapeutics is a clinical-stage biotechnology company, focused on developing drugs that block oncogenic pathways using multi-node inhibition. Shares of Faeth Therapeutics touched a 52-week high of $42.14 during intraday trading on Tuesday. The company recorded a net loss of $16 million in the second quarter of 2026, compared to $4.9 million a year ago. The company is advancing the combination therapy PIKTOR for the treatment of HR+/HER- breast cancer in a Phase 1/2 trial, with interim data expected in 2027. The therapy is also being evaluated in a Phase 2 trial for endometrial cancer, with topline data expected in the second half of 2026. This Day In History:

On this day in 1903, pharmacologist Marthe Vogt was born. The German-British scientist pioneered early research into neurotransmitters and their fundamental role in nerve signalling. After fleeing Nazi Germany, Vogt published a paper proving the function of acetylcholine in muscle movement, and highlighted the importance of epinephrine and norepinephrine in brain cell communication. A number of modern anti-depressant therapies were formulated based on her findings.